Company News-Bio-Thera Solutions, Ltd.

2025-08-26

Guangzhou, China– August , 2024 – Inc. “The EC approval of BAT2206 is anothersignificant accomplishment for Bio-Thera as...

查看详情

12-022022

Bio-Thera Solutions Announces BAT8006 (Folate-Receptor-α-ADC) and BAT8008 (Trop2-ADC) Poster Presentations at the 2022 San Antonio Breast Cancer Symposium

Guangzhou, China --(BUSINESS WIRE)--Bio-Thera Solutions, a commercial-stage biopharmaceutical company developing apipeli...
11-012022

Bio-Thera Solutions Initiates Phase III Clinical Trial for BAT2306, a Proposed Biosimilar of Cosentyx® (Secukinumab)

Guangzhou, China --(BUSINESSWIRE)--Bio-Thera Solutions, Ltd. (688177.SH), a commercial-stage pharmaceuticalcompany, toda...
10-152022

Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT2606, a Proposed Biosimilar of Nucala® (mepolizumab)

Guangzhou, China --(BUSINESSWIRE)-- Bio-TheraSolutions, Ltd. (SH: 688177),a commercial-stage biopharmaceutical company, ...